Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 7, 2008, Pages 2329-2336

  Maekawa, Kiyoshi ^a   Shoji, Tetsuo ^b   Emoto, Masanori ^b   Okuno, Senji ^a   Yamakawa, Tomoyuki ^a   Ishimura, Eiji ^b   Inaba, Masaaki ^b   Nishizawa, Yoshiki ^b  

^a OSAKA CITY UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaemia; Atherosclerosis; Cardiovascular disease; Haemodialysis; Mortality risk

Indexed keywords

PARATHYROID HORMONE;

ADULT; AGED; ANEMIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ANEMIA; ATHEROSCLEROSIS; CAROTID ARTERIES; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMATOCRIT; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 46849117537     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm929     Document Type: Article

References (41)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
3. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295
4. Shoji T, Emoto M, Tabata T et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 2002; 61: 2187-2192
5. Shinohara K, Shoji T, Tsujimoto Y et al. Arterial stiffness in predialysis patients with uremia. Kidney Int 2004; 65: 936-943
6. Kimoto E, Shoji T, Shinohara K et al. Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol 2006; 17: 2245-2252
7. Kawagishi T, Nishizawa Y, Konishi T et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995; 48: 820-826
8. Shoji T, Nishizawa Y, Kawagishi T et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998; 9: 1277-1284
9. London GM, Marchais SJ, Safar ME et al. Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990; 37: 137-142
10. Shoji T, Emoto M, Shinohara K et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 2117-2124
11. Nishizawa Y, Shoji T, Maekawa K et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2003; 41: S76-S79
12. Kalantar-Zadeh K, Kopple JD, Block G et al. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001; 12: 2797-2806
13. Grunze M, Kohlmann M, Mulligan M et al. Mechanisms of improved physical performance of chronic hemodialysis patients after erythropoietin treatment. Am J Nephrol 1990; 10 (Suppl 2): 15-18, discussion 18-23
14. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
15. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
16. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1182-1187
17. Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287
18. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185
19. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2): ii1-ii47
20. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11-S145
21. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
22. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
23. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
24. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
25. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388
26. Mitka M. FDA sounds alert on anemia drugs. JAMA 2007; 297: 1868-1869
27. KDOQI Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
28. Hirakata H, Kanai H, Fukuda K et al. Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. Clin Nephrol 2000; 53: 354-361
29. Nussbaum SR, Zahradnik RJ, Lavigne JR et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-1367
30. Hosoi M, Nishizawa Y, Kogawa K et al. Angiotensin-converting enzyme gene polymorphism is associated with carotid arterial wall thickness in non-insulin-dependent diabetic patients. Circulation 1996; 94: 704-707
31. Kogawa K, Nishizawa Y, Hosoi M et al. Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes 1997; 46: 682-687
32. Emoto M, Nishizawa Y, Kawagishi T et al. Stiffness indexes beta of the common carotid and femoral arteries are associated with insulin resistance in NIDDM. Diabetes Care 1998; 21: 1178-1182
33. Fukumoto M, Shoji T, Emoto M et al. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000; 20: 703-707
34. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277
35. Ruschitzka FT, Wenger RH, Stallmach T et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000; 97: 11609-11613
36. Neunteufl T, Katzenschlager R, Hassan A et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111-118
37. Kobayashi K, Akishita M, Yu W et al. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis 2004; 173: 13-18
38. Otaki Y, Nakanishi T, Hasuike Y et al. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis 2004; 43: 1030-1039
39. Kalantar-Zadeh K, Don BR, Rodriguez RA et al. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37: 564-572
40. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-828
41. Gejyo F, Saito A, Akizawa T et al. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004; 8: 443-459